Semaglutide Overview

Semaglutide, an amino-acid peptide, is used in the treatment of type 2 diabetes and as an anti-obesity agent for weight management. Similar to the hormone GLP-1, it functions as a receptor agonist, enhancing insulin production and inhibiting glucagon release. It improves glycemic control in adults with type 2 diabetes and aids in long-term weight management in obese or overweight adults with weight-related comorbidities. Semaglutide also reduces food intake by decreasing appetite and delaying gastric emptying, contributing to body fat reduction.

Product Details

• Sequence: HXEGTFTSDVSSYLEGQAAK-OH.steric diacid-EFIAWLRGRG
• Molecular Formula: C187H291N45O59
• Molecular Weight: 4113.64 g/mol
• PubChem CID: 56843331
• CAS Number: 910463-68-2

Research Highlights

1. Long-term Weight Management: In the STEP 5 trial, semaglutide led to substantial and sustained weight loss over 104 weeks in adults with obesity or overweight with comorbidities, averaging a 15.2% reduction from baseline.
2. Cardiometabolic Health: Contributes to improvements in cardiometabolic risk factors like reduced waist circumference and lower systolic blood pressure, indicating potential for reducing cardiovascular event risks.
3. Treatment of Type 2 Diabetes: Approved for type 2 diabetes treatment due to its effectiveness in increasing insulin production and inhibiting glucagon production, addressing key aspects of diabetes management.
4. Obesity with Comorbidities: The higher-dose formulation is indicated for weight management in adults with obesity or being overweight with weight-related comorbidities, broadening its application beyond diabetes care.